Optimi Health exports psilocybin to United Kingdom
Analysis based on 25 articles · First reported Jun 02, 2026 · Last updated Jun 10, 2026
The completion of Optimi Health's first psilocybin export to the United Kingdom for a Phase 2 clinical trial, alongside its ongoing supply to Australia and plans for the United States and Europe, is expected to positively impact Optimi Health's stock price. This expansion demonstrates the company's growing international presence and its capability as a vertically integrated GMP supplier in the regulated psychedelic drug market, potentially attracting more investors to the nascent psychedelic medicine industry.
Optimi Health, a pharmaceutical manufacturer of regulated psychedelic drug products, has completed its first export of naturally derived psilocybin, including biomass and 5mg capsules, to the United Kingdom. This shipment will support a planned Phase 2 clinical trial for treatment-resistant depression. The export was authorized by Canada — Health Canada and the UK United Kingdom — Home Office. The psilocybin capsules use the same formulation currently prescribed to patients in Australia. Optimi Health also completed a GMP production run of its 5mg psilocybin finished drug product, with additional product earmarked for upcoming clinical research in the United States and clinical trials in Europe. CEO Dane Stevens emphasized Optimi Health's unique position as a vertically integrated GMP supplier, capable of serving both commercial markets and clinical trials from its single licensed facility in Canada.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard